Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Plans to Advance Lung Cancer Drug into Clinic

Premium

Benitec Biopharma this week announced that it intends to move its non-small cell lung cancer drug candidate Tribetarna into clinical trials following positive preclinical data generated in collaboration with the Children’s Cancer Institute Australia.

The company said it will use a clinical research organization to manage a planned phase I/IIa study of the expressed RNAi drug, which could begin in the fourth quarter of 2014.

Start of that trial, however, will depend on Benitec obtaining needed funding, it said.

In April, the company announced that Tribetarna, which beta III tubulin, boosted the survival of an orthotopic mouse cancer model when used in combination with chemotherapy, compared with chemotherapy alone (GSN 4/11/2013).

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.